Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.
Fauvre A, Machu M, Merienne A, Vie N, Bessede T, Robin M, Garambois V, Taffoni C, Laguette N, Gervois-Segain N, Jarry A, Labarriere N, Allory Y, Larbouret C, Gros L, Tosi D, Solit DB, Pourquier P, Houédé N, Gongora C. Fauvre A, et al. Among authors: labarriere n. Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011. Clin Transl Med. 2024. PMID: 39269751 Free PMC article. No abstract available.
Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V. Lesimple T, et al. Among authors: labarriere n. Clin Cancer Res. 2006 Dec 15;12(24):7380-8. doi: 10.1158/1078-0432.CCR-06-1879. Clin Cancer Res. 2006. PMID: 17189411 Clinical Trial.
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Ducoin K, Oger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-Segain N. Ducoin K, et al. Among authors: labarriere n. Oncoimmunology. 2022 Mar 9;11(1):2046931. doi: 10.1080/2162402X.2022.2046931. eCollection 2022. Oncoimmunology. 2022. PMID: 35295095 Free PMC article.
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.
Cadiou G, Beauvais T, Marotte L, Lambot S, Deleine C, Vignes C, Gantier M, Hussong M, Rulli S, Jarry A, Simon S, Malissen B, Labarriere N. Cadiou G, et al. Among authors: labarriere n. Oncoimmunology. 2024 Jul 8;13(1):2376782. doi: 10.1080/2162402X.2024.2376782. eCollection 2024. Oncoimmunology. 2024. PMID: 38983599 Free PMC article.
CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease.
Sarrabayrouse G, Bossard C, Chauvin JM, Jarry A, Meurette G, Quévrain E, Bridonneau C, Preisser L, Asehnoune K, Labarrière N, Altare F, Sokol H, Jotereau F. Sarrabayrouse G, et al. Among authors: labarriere n. PLoS Biol. 2014 Apr 8;12(4):e1001833. doi: 10.1371/journal.pbio.1001833. eCollection 2014 Apr. PLoS Biol. 2014. PMID: 24714093 Free PMC article.
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N. Marotte L, et al. Among authors: labarriere n. J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. J Immunother Cancer. 2020. PMID: 32001504 Free PMC article.
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Marotte L, Capitao M, Deleine C, Beauvais T, Cadiou G, Perrin J, Chérel M, Scotet E, Guilloux Y, Bruchertseifer F, Morgenstern A, Jarry A, Gaschet J, Labarriere N. Marotte L, et al. Among authors: labarriere n. Oncoimmunology. 2021 Jun 27;10(1):1940676. doi: 10.1080/2162402X.2021.1940676. eCollection 2021. Oncoimmunology. 2021. PMID: 34239774 Free PMC article.
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.
Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L. Fidelle M, et al. Among authors: labarriere n. Science. 2023 Jun 9;380(6649):eabo2296. doi: 10.1126/science.abo2296. Epub 2023 Jun 9. Science. 2023. PMID: 37289890
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.
Ollier J, Kervarrec T, Samimi M, Benlalam H, Aumont P, Vivien R, Touzé A, Labarrière N, Vié H, Clémenceau B. Ollier J, et al. Among authors: labarriere n. Cancer Immunol Immunother. 2018 Aug;67(8):1209-1219. doi: 10.1007/s00262-018-2176-2. Epub 2018 May 28. Cancer Immunol Immunother. 2018. PMID: 29808366 Free PMC article.
81 results